On Thursday,Shares of Marathon Oil Corporation (NYSE:MRO), subtract -1.07% and closed at $14.78 in the last trading session. The last trading range of the stock ranges between $14.52 and $14.93. The company’s Market capitalization is $12.41 Billion with the total Outstanding Shares of 847.26 million. Marathon Oil Corporation operates as an energy company. It operates through three segments: North America E&P, International E&P, and Oil Sands Mining. The North America E&P segment develops, explores for, produces, and markets crude oil and condensate, natural gas liquids, and natural gas in North America. The International Exploration and Production segment explores for, produces, and markets crude oil and condensate, natural gas liquids, and natural gas in Equatorial Guinea, Gabon, the Kurdistan Region of Iraq, Libya, and the United Kingdom; and produces and markets products manufactured from natural gas, such as liquefied natural gas and methanol in Equatorial Guinea. The Oil Sands Mining segment mines, extracts, and transports bitumen from oil sands deposits in Alberta and Canada; and upgrades the bitumen to produce and market synthetic crude oil and vacuum gas oil. As of December 31, 2015, it had rights to take part in developed and undeveloped leases totaling about 32,000 net acres. The company was formerly known as USX Corporation and changed its name to Marathon Oil Corporation in July 2001.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), jumped 6.58% and closed at $4.05 in the last trading session. The last trading range of the stock ranges between $3.81 and $ 4.90. The company’s Market capitalization is $43.70Million with the total outstanding Shares of 9.94million. Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) and Specialised Therapeutics Asia (“STA”) recently declared the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the territories of Australia and New Zealand (the “Territory”). Zoptrex™, a novel synthetic peptide carrier linked to doxorubicin, is presently undergoing a fully-enrolled Phase 3 clinical trial to evaluate the compound in endometrial cancer. The Company anticipates to complete the Phase 3 clinical trial in 2016 and, if the results of the trial warrant doing so, to submit a new drug application for Zoptrex™ to the United States Food and Drug Administration (FDA) in the first half of 2017. Zoptrex™ is the Company’s projected tradename for zoptarelin doxorubicin. The projected tradename is subject to approval by the FDA.
Under the terms of the License Agreement, Aeterna Zentaris will be entitled to receive a non-refundable upfront payment in consideration for the license to STA of the Company’s intellectual property related to Zoptrex™ and the grant to STA of the right to commercialize Zoptrex™ in the Territory. STA has also agreed to make additional payments to the Company upon achieving certain pre-established regulatory and commercial milestones, in addition to double-digit royalties on future net sales of Zoptrex™ in the Territory. STA will be responsible for the development, registration, reimbursement and commercialization of the product in the Territory. The Company and STA have also reached a supply agreement, following which the Company will supply Zoptrex™ to STA for the duration of the license agreement.
Credit Suisse Group AG (ADR) (NYSE:CS), lost -2.14% and closed at $12.83 in the last trading session. The last trading range of the stock ranges between $12.69 and $12.87. The company’s Market capitalization is $26.63Billion with the total outstanding Shares of 2.08 million. During the 52-week trading session the minimum price at which share price traded, registered at $10.01 and reached to max level of $26.30. Commodities raised in September, broadly because of supply fundamental factors, according to Credit Suisse Asset Administration.
The Bloomberg Commodity Index Total Return performance was positive for the month, with 18 out of 22 Index constituents posting gains.
Credit Suisse Asset Administration observed the following:
Industrial Metals was the best performing sector, up 5.21%, led by Nickel amid reports that the Philippines may suspend additional mines for failing to meet environmental standards as a result of the government’s audit.
Agriculture ended 4.25% higher. Sugar gained the most as UNICA, the Brazilian Sugarcane Industry Association, stated lower-than-expected domestic cane yields. In addition, the International Sugar Organization forecasted a global sugar deficit for the 2016-2017 season.
Energy gained 4.17%, led by Gasoline, because of tightening supplies in the US. The US Energy Information Administration stated much larger-than-expected decreases in gasoline inventories at the starting of the month.
Precious Metals raised 1.13%, led by Silver, as the US Federal Reserve (Fed) kept interest rates unchanged while reducing their outlook for future rate hikes.
Livestock declined the most, down 13.24%, as higher supply expectations weighed on the sector broadly.